Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer

Cancer Science

Volumn 103, Issue 4, 2012, Pages 638-644

  Terazaki, Yasuhiro ^a   Yoshiyama, Koichi ^a   Matsueda, Satoko ^a   Watanabe, Noriko ^a   Kawahara, Akihiko ^b   Naito, Yoshiki ^a   Suekane, Shigetaka ^a   Komatsu, Nobukazu ^a   Ioji, Tetsuya ^a   Yamada, Akira ^c   Mine, Takashi ^a   Terasaki, Mizuhiko ^a   Itoh, Kyogo ^a   Takamori, Shinzo ^a   Sasada, Tetsuro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMRUBICIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CANCER VACCINE; CARBOPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; DIPEPTIDYL PEPTIDASE IV; ETOPOSIDE; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; HLA ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; IRINOTECAN; NAVELBINE; PACLITAXEL; PEPTIDE VACCINE; SERUM AMYLOID A; TOPOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PROGNOSIS; CD3+ T LYMPHOCYTE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; DRUG FEVER; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPONATREMIA; INJECTION SITE REACTION; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MICROALBUMINURIA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY LUNG SMALL CELL CANCER; SIDE EFFECT; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR ASSOCIATED LEUKOCYTE; WHOLE BODY RADIATION;

AGED; ANTIGENS, CD3; CANCER VACCINES; DIPEPTIDYL PEPTIDASE 4; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; VACCINES, SUBUNIT;

EID: 84858996598     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02202.x     Document Type: Article

References (24)

1. William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011; 8: 611-9.
2. Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 2011; 37: 143-50.
3. Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien ME. Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 2010; 102: 629-38.
4. Bridle BW. Neuroendocrine cancer vaccines in clinical trials. Expert Rev Vaccines 2011; 10: 811-23.
5. Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev Vaccines 2010; 9: 323-35.
6. Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011; 29: 337-44.
7. Noguchi M, Kakuma T, Uemura H et al. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 2010; 59: 1001-9.
8. Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009; 58: 1843-52.
9. Yanagimoto H, Shiomi H, Satoi S et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795-801.
10. Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10: 929-37.
11. Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10: 1266-79.
12. Yoshida K, Noguchi M, Mine T et al. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncol Rep 2011; 25: 57-62.
13. Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 970-6.
14. Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64: 535-45.
15. Kinoshita Y, Kuratsukuri K, Landas S et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006; 30: 628-36.
16. Quintero IB, Araujo CL, Pulkka AE et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res 2007; 67: 6549-54.
17. Wang Y, Harada M, Yano H et al. Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 2005; 28: 535-41.
18. Wang Y, Harada M, Yano H et al. Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients. Oncol Rep 2006; 15: 317-21.
19. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 878-87.
20. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010; 10: 983-91.
21. Neninger E, Díaz RM, de la Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6: 145-50.
22. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23: 6854-64.
23. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001; 7: 1181-91.
24. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008; 29: 295-301.